Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Key Points

• CFO Andrew Dickinson sold 3,000 shares on April 15 under a pre‑arranged Rule 10b5‑1 plan at an average $140.96, totaling $422,880 and trimming his stake by 1.67% to 176,191 shares.
• Gilead beat Q1 expectations with $1.86 EPS on $7.93B revenue and set FY2026 guidance of $8.45–$8.85 EPS, while raising the quarterly dividend to $0.82 (annualized $3.28; ~2.4% yield).
• Wall Street is broadly positive—24 Buys vs. 4 Holds with a consensus price target of $156.77—but the stock traded near $138.55 amid worries over HIV drug persistence and some downward EPS revisions.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the sale, the chief financial officer directly owned 176,191 shares in the company, valued at approximately $24,835,883.36. This trade represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Price Performance

GILD stock traded down $1.22 during mid-day trading on Thursday, hitting $138.55. The stock had a trading volume of 3,431,818 shares, compared to its average volume of 6,915,050. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The firm has a market capitalization of $171.97 billion, a P/E ratio of 20.47, a P/E/G ratio of 1.87 and a beta of 0.39. The firm has a fifty day simple moving average of $144.86 and a 200 day simple moving average of $131.05. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion for the quarter, compared to analysts' expectations of $7.68 billion. During the same period last year, the firm posted $1.90 earnings per share. The firm's quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Friday, March 13th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's dividend payout ratio is currently 48.45%.

Institutional Investors Weigh In On Gilead Sciences

A number of hedge funds have recently added to or reduced their stakes in the business. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences in the fourth quarter valued at $25,000. Vermillion & White Wealth Management Group LLC increased its position in Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 85 shares in the last quarter. Quattro Advisors LLC acquired a new position in Gilead Sciences during the 4th quarter worth approximately $26,000. Wealth Preservation Advisors LLC boosted its stake in Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC bought a new position in Gilead Sciences during the 4th quarter valued at $28,000. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on GILD shares. Wall Street Zen upgraded shares of Gilead Sciences from a "buy" rating to a "strong-buy" rating in a report on Saturday, March 14th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the company a "buy" rating in a research report on Wednesday, February 11th. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 11th. Leerink Partners raised their target price on Gilead Sciences from $146.00 to $148.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 11th. Finally, Morgan Stanley lifted their price objective on Gilead Sciences from $171.00 to $175.00 and gave the stock an "overweight" rating in a research note on Friday, April 10th. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $156.77.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Wells Fargo maintained a buy rating on Gilead, reaffirming confidence in the company’s fundamentals and longer‑term outlook. Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)
• Positive Sentiment: The U.S. government expanded a partnership with Gilead and The Global Fund to supply 1 million doses of lenacapavir (LEN) to help reduce HIV transmission — a material public‑health win that supports future demand and reputation. US-Led Partnership To Provide 1 Mln Lenacapavir To Help End HIV Transmission
• Positive Sentiment: A Citi analyst said GILD’s stock is likely to rise, adding another buy‑side voice that could support investor sentiment if near‑term uncertainties ease. Gilead Sciences NASDAQ: GILD Stock Price Expected to Rise, Citigroup Analyst Says
• Neutral Sentiment: Recent commentary and valuation pieces highlight that Gilead has produced strong multi‑year returns and now draws attention on valuation metrics and its large biopharma revenue base — useful context but not a near‑term catalyst. Gauging Gilead Sciences (GILD) Valuation After Strong Multi‑Year Shareholder Returns
• Neutral Sentiment: Gilead has been a trending stock on some platforms and routine earnings timing/preview stories are circulating; these keep the name in focus but aren’t driving today’s move. Gilead Sciences, Inc. (GILD) Is a Trending Stock
• Negative Sentiment: RBC flagged that persistence (ongoing use) for Gilead’s recently launched HIV drug is weaker than expected nine months post‑launch — a direct demand/usage concern that likely pressured the stock. Gilead Sciences' HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says
• Negative Sentiment: Zacks Research trimmed Q1–Q4 and FY2026 EPS estimates in a batch of cuts, signaling analyst downward revisions that increase downside risk to near‑term earnings expectations. Zacks Research Lowers Gilead EPS Estimates
• Negative Sentiment: Late‑session weakness in health‑care indices amplified selling pressure across names, contributing to Gilead’s decline despite company‑specific positives. Sector Update: Health Care Stocks Decline Late Afternoon

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.